1. Introduction {#s0005}
===============

Motor signs and symptoms of Parkinson\'s disease (PD) are a result of the degeneration of large parts of the substantia nigra (SN). PD also involves the degeneration of multiple neurotransmitter systems (e.g. noradrenaline, serotonin, acetylcholine ([@bb0150])), which are connected to non-motor disorders that can affect cognitive ([@bb0530]; for a review, see [@bb0240]) and neuropsychiatric domains, such as cognitive impairment (leading to dementia in most patients), depression, anhedonia, and apathy (for a review, see [@bb0210]). It is currently thought that the pre-symptomatic stages of PD are mostly associated with subcortical and sympathetic nervous system degenerations ([@bb0160]). Cortical lesions appear in later stages of the disease ([@bb0130]).

1.1. Magnetic Resonance Imaging in PD {#s0010}
-------------------------------------

As regards our knowledge of PD pathophysiology, recent neuroimaging methods make it possible to investigate anatomy and impact of brain alterations, on the basis of functional, structural and diffusion data acquisitions, three complementary techniques to assess brain changes related to neurodegenerative diseases like PD. Resting-state functional Magnetic Resonance Imaging (fMRI) can be used to study brain connectivity and the alterations of functional networks. A recent review of the literature provided interesting insights into the functional alterations in PD ([@bb0385]): mainly, PD induces functional dysfunctions particularly in the sensorimotor, visual and basal ganglia networks. It is reasonable to argue that fMRI data depends on several parameters, such as the dopaminergic medication state (e.g., [@bb0470], [@bb0235]) or the fMRI acquisition parameters (e.g. [@bb0385]). Concerning anatomical MRI, voxel-based morphometry (VBM) can be used to study the volume of gray matter ([@bb0020]). Recent VBM meta-analyses demonstrated a cortical atrophy in PD patients in the left inferior frontal gyrus, superior temporal gyrus, insula and parietal areas (for a review, see [@bb0355], [@bb0450]; ([@bb0550]), but also in the left-sided parahippocampal gyrus, insula and superior temporal gyrus in younger patients, as well as a correlation between disease duration and motor impairment and gray matter reduction in the left inferior frontal gyrus ([@bb0355]). While fMRI allows the study of functional connectivity by assessing neuronal (dys)functioning related to PD, structural MRI adds information regarding anatomical changes, and particularly cortical lesions that are also involved in the disease progression. Functional and structural MRI data contribute to a substantial, but still partial, understanding of PD pathophysiology. In order to enhance this knowledge, DTI allows the study of white fiber integrity, which is also impacted by the neurodegenerative processes.

1.2. Diffusion tensor imaging to understand PD pathophysiology {#s0015}
--------------------------------------------------------------

DTI is an approach used to estimate changes in white matter integrity, which makes it possible to study the structure of cerebral tissue, such as the trajectories in white matter bundles and the orientation of fibers ([@bb0075], [@bb0305]). It is based on the measurement of "*the random motion of water molecules in fluid water*" ([@bb0460]), particularly suited to neural fibers ([@bb0245]). Two crucial measures that can be used are the mean diffusivity (MD) and the fractional anisotropy (FA) ([@bb0025]). MD refers to the diffusion of water molecules in organic tissues. Increased MD can be problematic since it indicates that the tissues do not retain water molecules, possibly because of an enlargement of the extracellular space, suggesting degeneration of the tissue ([@bb0465]). FA characterizes the orientation distribution of the random movement of water molecules. Anisotropy refers to a non-uniform diffusion of water molecules in tissues. The closer to 1 the FA value is, the more anisotropic this diffusion is. Conversely, for an FA value close to 0, the movement of water molecules would be isotropic, suggesting damaged tissue when measured in white matter ([@bb0430]). In other words, FA and MD make it possible to measure demyelination as a sign of white matter alteration ([@bb0455]); while this is generally accepted, changes in FA or MD values can be explained by other cellular changes unrelated to white-matter integrity, or by crossing fibers ([@bb0005], [@bb0190]). FA and MD have been used as markers of structural damage in some pathologies (e.g. for a review of mild cognitive impairment and Alzheimer\'s disease: [@bb0445]; epilepsy: [@bb0350]; depression: [@bb0520]; amyotrophic lateral sclerosis: [@bb0115]). DTI can also be used to study structural changes induced by training ([@bb0415], [@bb9600]) and has been hypothesized to reveal compensatory reorganization of specific areas in certain pathologies for human ([@bb0555]) and animal models ([@bb0085]). DTI holds promise for contribution to the differential diagnosis between PD and atypical Parkinsonian syndromes (for reviews, see [@bb0070], [@bb0275], [@bb0440]). Since the early 2000s, the number of comparative studies between PD individuals and healthy controls has been growing.

Concerning PD, previous reviews and meta-analyses focused on the differential diagnosis between PD and atypical Parkinsonian syndromes (see [@bb0070], [@bb0275], [@bb0440]) and the comparisons between PD patients and healthy controls in the SN ([@bb0435]). This focus on the SN represents so far the main consensual information related to DTI exploration of PD neurodegenerative processes. Actually, despite recent literature reviews on DTI ([@bb0145]) and fMRI resting state ([@bb0385]), and unlike for VBM (e.g., [@bb0355]), a whole-brain meta-analysis for DTI in PD was not available so far. Considering PD neurodegeneration of both cortical and sub-cortical structures is of particular interest since it would contribute to understand PD pathophysiology from a more global perspective. Our objective in this article is to provide this missing meta-analysis in order to further reinforce knowledge on PD pathophysiology, to address the heterogeneities in the literature, and identify convergence of findings.

2. Methods {#s0020}
==========

2.1. Literature search {#s0025}
----------------------

To identify the articles for our literature review, we searched for publications on the Medline®/PubMed database (<http://www.ncbi.nlm.nih.gov/pubmed/>), without any temporal restriction. To run our search, the keyword 'Parkinson' was associated with the following terms: '*diffusion tensor imaging*', '*tractography*', '*fractional anisotropy*' and '*mean diffusivity*'. After excluding duplicates (n = 181) and inappropriate articles (n = 177), we retained for analysis 39 relevant studies published between 2006 and 2016, reporting original research (editorials, letters to editors, discussions and reviews were excluded) with exploitable data ([Fig. 1](#f0005){ref-type="fig"}). In total, data from 1855 individuals were considered in this review: 1087 PD patients and 768 healthy individuals. Among the 39 articles, we retained 38 studies for the FA analysis and 25 for the analysis of MD. We considered only the studies reporting the FA and/or the MD, since other indicators (such as axial and radial diffusivity) were less reported in the literature and that the number of data was insufficient to perform a meta-analysis. Tractography studies have not been included in our analysis: although tractography is increasingly being used to map fiber pathways relevant to PD ([@bb0390]), it is quite complicated in terms of methodology and its accuracy is still debated ([@bb0475]).Fig. 1Study selection for the meta-analysis.\*No data available: for these studies, the means and standard deviations of FA and MD, for healthy controls and PD patients, were not directly available in the articles. \*\*Surgical studies: these articles involved PD patients with brain lesions.Fig. 1

2.2. Main variables {#s0030}
-------------------

Among the 39 articles selected, we extracted the values (means and standard deviations) of FA and/or MD directly available and for each region specified in the selected publications. From these data, we considered two levels of classification of brain regions. The first one, so-called "*anatomical level*", referred to the specific regions reported in the selected publications (e.g. SN; caudate nucleus; olfactory regions). The second one corresponded to the "*clustering level*" that we generated by gathering together the anatomical regions of the first level: 4 clusters were then identified, namely cortical, subcortical, white fiber, and cerebellum.

The quantitative statistical meta-analysis was performed using the OpenMeta\[Analyst\] software (MetaAnalyst, Tufts Medical Center ([@bb0505])). This software is a visual front-end for the R package ([www.r-project.org](http://www.r-project.org){#ir0010}; Metafor; [@bb0500]). We used this software with default parameters for comparing two participant groups (PD individuals vs. healthy controls). As the main variables for our meta-analysis, results from the different studies were considered on the basis of the disease effect size (D~ES~) to account for inter-study heterogeneity (e.g., demographic, clinical, and technical information). In this context, the D~ES~ corresponds to a standardized effect size, Z-scored, which considers the difference in standard deviations between PD patients and healthy controls, both for FA (FA-D~ES~) and MD (MD-D~ES~). The D~ES~ score was calculated using the Hedges\' g corresponding to the following calculation:$$D_{ES} = \frac{\text{Mean}\ {PD} - \text{Mean}\ {HC}}{S^{\ast}}$$where S\* represents the pooled standard deviation of the two groups. In addition, as implemented within the software OpenMeta\[Analyst\], the D~ES~ scores were corrected for a slight positive bias within the function ([@bb0165], [@bb0500]).

Following this calculation, fiber degradation in PD is expected to be associated with negative FA-D~ES~ scores and positive MD-D~ES~ scores; conversely, positive FA-D~ES~ scores and negative MD-D~ES~ scores should refer to brain reorganization. Calculations were based on a random effect model using DerSimonian and Laird\'s method, for which the effects are supposed to vary between studies ([@bb0035]). The statistical significance level for FA-D~ES~ and MD-D~ES~ was set at p \< 0.05 in our analyses.

2.3. Co-variables {#s0035}
-----------------

For our analyses, we were also interested in participant demographic and clinical characteristics, if available, such as the gender and age of all individuals, as well as the disease duration of PD patients ([Table 1A](#t0005){ref-type="table"}). We did not consider the motor scores of the UPDRS - Unified Parkinson\'s Disease Rating Scale ([@bb0110]) - because they were not available for all studies, and because the medication state of the PD patients varied across studies (18 studies with patients under medication, 8 without medication, and 12 without this information). We also considered MRI acquisition parameters (field strength \[T\]; voxel size \[mm^3^\]; number of directions for the DTI; echo time \[TE\]; repetition time \[TR\]; Bihan factor \[b\]; [Table 1B](#t0010){ref-type="table"}) as co-variables.Table 1ADemographic and clinical information of studies involved in meta-analysis.Table 1ANStudyGroupParticipantsGender (F/M)Mean age ± SD (years)Mean UPDRS-III ± SD \[on/off [l]{.smallcaps}-Dopa\]Mean disease duration ± SD (years)1[@bb9500]PD126/665.1 ± 7.322.2 ± 9.9 \[on\]6.9 ± 2HC127/563.4 ± 6.3----2[@bb9505]PD2623/371.2 ± 9.231.4 ± 17.6 \[on\]8.7 ± 5.5PD - sleepiness118/372.2 ± 7.242.2 ± 11.2 \[on\]9.6 ± 5HC107/372.4 ± 6.4----3[@bb0270]PD2622/470 ± 8.630.1 ± 14.4 \[on\]8.3 ± 5.6PDD119/275 ± 7.745.3 ± 17 \[on\]10.5 ± 4.3HC10na70.7 ± 17.4----4[@bb0185]PD29na67 ± 9na \[na\]4.8 ± 3.3HC19na73 ± 5----5[@bb0125]PD105/563.8 ± 15.714.2 ± 6.5 \[on\]3.4 ± 2.9HC105/558.1 ± 8----6[@bb0030]PD147/757.9 ± 7.719.5 ± 7.2 \[na\]2.9 ± 1.56HC148/658.6 ± 10.6----7[@bb0285]PD103/763.7 ± 6.7na \[on\]naHC103/764.4 ± 9.9----8[@bb0360]PD3010/2061.9 ± 11.112 ± 5.9 \[on\]4.5 ± 2.5HC2211/1157.4 ± 9.7----9[@bb0525]PD2912/1770.8 ± 4.616.8 ± 7.6 \[na\]naPDD61/571.4 ± 4.219.5 ± 8.5 \[na\]naHC157/870.7 ± 4----10[@bb0405]PD146/856 ± 4.8na \[on\]2.5 ± 1.76HC146/855.2 ± 6.2----11[@bb0050]PD257/1865 ± 8.418.6 ± 8.7 \[on\]4.4 ± 4HC257/1865 ± 8.9----12[@bb0095]PD - early158/760.2 ± 10.117.1 ± 9.4 \[off\]0.5 ± 0.5PD - mild146/859.2 ± 621.6 ± 11 \[off\]3.3 ± 1.1PD - later123/963.4 ± 7.934.6 ± 20.3 \[off\]10.4 ± 4.3HC2815/1359.8 ± 7----13[@bb0215]PD156/969.8 ± 5.919 ± 12 \[on\]5.88 ± 4.8PDD157/871.3 ± 5.627.1 ± 9.9 \[on\]11.58 ± 8.04HC159/669.5 ± 6.9----14[@bb0370]PD117/460.4 ± 9.323.5 ± 9.5 \[off\]5.7 ± 4.2HC126/660.8 ± 8.5----15[@bb9510]PD61/568.59 ± 211.83 ± 2.5 \[na\]naPD - depression61/570.95 ± 2.916.67 ± 11.6 \[na\]naHC61/570.69 ± 2.4--na16[@bb0560]PD120/1267.4 ± 826.3 ± 12.2 \[off\]naHC200/2067.2 ± 8--na17[@bb0080]PD2414/1062.1 ± 8.630.2 ± 12.2 \[na\]4.7 ± 3.4PD - MCI3015/1565.1 ± 11.842.4 ± 14 \[na\]5.1 ± 2.9PDD105/569 ± 9.756 ± 15.3 \[na\]6.8 ± 6.86HC2110/1160.1 ± 13.6----18[@bb0220]PD178/965 ± 9.3na \[on\]6.7 ± 4.6HC155/1064 ± 12.7----19[@bb9550]PD2012/871.6 ± 4.3na \[on\]7.8 ± 4.45PDD2010/1071.7 ± 5.3na \[on\]12.2 ± 7.58HC2010/1072.7 ± 3.3----20[@bb0345]PD2111/1062.2 ± 7na \[na\]6.8 ± 4.1HC2110/1162.3 ± 5.6----21[@bb0380]PD152/1362.7 ± 7.730 ± 8.9 \[off\]10.5 ± 7.3HC177/1062.9 ± 9----22[@bb0425]PD1610/668.1 ± 6.120 ± 10.3 \[off\]3.7 ± 3.7HC148/667.3 ± 3.7----23[@bb0435]PD3216/1664.8 ± 11.826.1 ± 13.9 \[on\]naHC2716/1159.9 ± 10.5----24[@bb9515]PD135/866.8 ± 841 ± 11.1 \[na\]6.4 ± 6)HC61/565.3 ± 10.8----25[@bb0060]PD214/1772 ± 4.8na \[on\]naPD - gait disorder257/1873.3 ± 6.2na \[on\]naHC193/1671.5 ± 5----26[@bb9520]PD126/665.4 ± 10na \[on\]7.1 ± 4.5HC105/567.6 ± 10.1----27[@bb0290]PD209/1160 ± 1124.9 ± 10 \[on\]1.8 ± 0.8HC209/1160 ± 8----28[@bb0195]PD3115/1669.4 ± 8na \[na\]naHC3416/1869.3 ± 8----29[@bb9525]PD168/862.2 ± 8.621 \[na\]11.1 ± 4.5HC169/760.1 ± 7.2----30[@bb9530]PD203/1764 ± 934 ± 14 \[na\]naHC228/1461 ± 13----31[@bb0490]PD154/1167.6 ± 5.632.5 ± 9.1 \[on\]7.6 ± 5.3PD - FOG113/868.6 ± 8.736.6 ± 18.3 \[on\]9.5 ± 3.7HC154/1168.1 ± 6.5----32[@bb0570]PD5018/3259.7 ± 9.221.9 ± 7.8 \[na\]naHC276/2156.8 ± 10.7----33[@bb9535]PD7246/2666.8 ± 5.414.9 ± 3.9 \[off\]1.1 ± 0.6HC7244/2866.1 ± 6.8----34[@bb0225]PD5826/3268.8 ± 7.518 ± 8.5 \[on\]7.4 ± 4.4HC3618/1870.8 ± 8.4----35[@bb9540]PD149/566.1 ± 6.120.3 ± 7.8 \[na\]7.3 ± 3.7PD -- VH103/769.2 ± 5.222.9 ± 5.1 \[na\]7.2 ± 3.7HC158/768.5 ± 6.6----36[@bb9545]PD146/869.7 ± 7.222.4 ± 10.6 \[na\]4.4 ± 3.7PD -- RBD2412/1269.8 ± 6.412.4 ± 2.5 \[na\]6.2 ± 2.9HC2512/1368.5 ± 6.6----37[@bb0260]PD -- early186/1256.8 ± 6.826.2 ± 9.2 \[off\]3.9 ± 2.2PD -- mild186/1258.3 ± 6.834.6 ± 12.5 \[off\]5.5 ± 2.2HC144/1056.3 ± 6.4----38[@bb0310]PD219/1261.1 ± 7.731.4 ± 10 \[off\]5.5 ± 3.4HC209/1161.1 ± 9----39[@bb0375]PD408/3267.8 ± 5.417.6 ± 10.7 \[on\]7.5 ± 5.1HC407/3368.2 ± 4.6----**1087 PDMin**--**Max475/58456**--**7511.83**--**560.5**--**12.2768C321/41855.2**--**73**----[^1]Table 1BTechnical data of studies involved in meta-analysis.Table 1BNStudyTotal participantsField strength (T)b valueTETRAcquisition voxel size (mm^3^)Number of directionsFAMD1[@bb9500]241.5130010740001.875 × 1.875 × 2.560√√2[@bb9505]471.5100096.280001.875 × 1.875 × 46√3[@bb0270]471.5100096.280001.875 × 1.875 × 46√4[@bb0185]481.5100096.413,0002.03 × 1.625 × 5ns√5[@bb0125]201.510007942001.875 × 1.875 × 2.512√√6[@bb0030]281.510007010,0002.1875 × 2.1875 × 312√√7[@bb0285]20310009493002 × 2 × 260√√8[@bb0360]52310008985001.8 × 1.8 × 1.830√√9[@bb0525]501.510008856000.86 × 0.86 × 36√√10[@bb0405]281.59007212,0002.03 × 2.03 × 331√√11[@bb0050]50310008985001.8 × 1.8 × 1.830√12[@bb0095]69310008283002 × 2 × 242√13[@bb0215]45310007054432 × 2 × 332√√14[@bb0370]2338006045000.9 × 0.9 × 312√15[@bb9510]181.510008856001.7 × 1.7 × 36√√16[@bb0560]32410007760002 × 2 × 36√√17[@bb0080]853100087.912,0003.4 × 3.4 × 316√18[@bb0220]32320007070413 × 3 × 320√√19[@bb9550]60310007054431.75 × 1.75 × 332√√20[@bb0345]421.5100010611,2002.5 × 2.5 × 2.564√21[@bb0380]32310008245001.33 × 2 × 48√√22[@bb0425]301.510009460001.8 × 1.8 × 36√√23[@bb0435]59310006074151 × 1 × 232√√24[@bb9515]19310009593002 × 2 × 260√√25[@bb0060]65310008682001.875 × 1.875 × 230√26[@bb9520]22320007070413 × 3 × 320√√27[@bb0290]40310009493002 × 2 × 260√√28[@bb0195]653100087.685001.846 × 1.875 × 530√29[@bb9525]32310008769192 × 2 × 2.560√30[@bb9530]42310005511,3042 × 2 × 232√31[@bb0490]413280011687002.5 × 2.5 × 2.575√√32[@bb0570]7731000889002 × 2 × 264√33[@bb9535]1443100076.460001.875 × 1.875 × 525√34[@bb0225]94320008040000.982 × 0.982 × 532√√35[@bb9540]393800666598.21.964 × 1.964 × 2ns√√36[@bb9545]633800666598.22 × 2 × 2ns√√37[@bb0260]50310008893001.875 × 1.875 × 1.964√√38[@bb0310]41310009216,0002.031 × 2.031 × 232√√39[@bb0375]80310008117,3001 × 1 × 170√**N = 1855Min1.5800559000.86 × 0.86 × 363825Max4280011617,3003.4 × 3.4 × 375**

2.4. Statistical analyses {#s0040}
-------------------------

Heterogeneity in a meta-analysis refers to the variation in outcomes between studies. The usual measure of heterogeneity is Cochran\'s Q, which is calculated as the weighted sum of squared differences between individual study effects and the pooled effect across studies. Cochran\'s Q test provides a p-value, with low p-values highlighting the presence of heterogeneity between studies without any size estimate. To improve the interpretation of our analyses, we also calculated the heterogeneity index (I^2^). This measure can be interpreted as the proportion of total variability explained by heterogeneity and refers to the percentage of variation across studies ([@bb0175]). I^2^ can be calculated from Q statistic (100% × \[Q − degrees of freedom\] / Q) and does not depend on the number of studies included in the meta-analysis. Thus, I^2^ highlights the inconsistency across studies and ranges from 0% (i.e. no heterogeneity) to 100% (i.e. the highest heterogeneity). Heterogeneity can be considered as low (0 \< I^2^ \< 30%), moderate (30 \< I^2^ \< 60%), substantial (50 \< I^2^ \< 90%) or considerable (75 \< I^2^ \< 100%). The statistical significance level for I^2^ was set at p \< 0.05 in our analyses.

We used three different R packages in order to conduct Pearson\'s correlations (Rcmdr package) to analyse the relationship between the main variables (FA-D~ES~ and MD-D~ES~) and several co-variables that are detailed above; graphical representations were performed using Hmisc and Corrplot R packages. In a second step, we have performed a Holm\'s correction for multiple correlation. The statistical significance level for the correlations was set at p \< 0.05. FA-D~ES~ and MD-D~ES~ were reported according to four anatomical regions: 1) subcortical nuclei; 2) white matter; 3) cortical areas; and 4) cerebellar regions. Thus, the FA-D~ES~ and MD-D~ES~ were generated by compiling together each value, from each study, of all regions included in the 4 brain territories that we pre-defined.

We do not discuss the data when FA-D~ES~ and MD-D~ES~ were reported by only one study, or when D~ES~ was significant only for FA or MD and significantly heterogeneous (I^2^).

2.5. Subset analysis of medication effects on SN {#s0045}
------------------------------------------------

We performed a specific analysis on the effect of dopaminergic state on FA-D~ES~ and MD-D~ES~ for SN. Some studies suggested that dopaminergic state can influence the results of functional (e.g., [@bb0470], [@bb0235]) and anatomical ([@bb0420]) MRI acquisition. However, "*the effects of medication on DTI are not known*" ([@bb0380]). It is conceivable that medication states played a role and contributed to the results of the DTI analyses. To test this hypothesis on the data involved in our study, we ran an additional meta-analysis that considered only the SN, and that separated off- and on-medication data for FA-D~ES~ and MD-D~ES~.

3. Results {#s0050}
==========

3.1. Demographic and clinical characteristics {#s0055}
---------------------------------------------

Demographic and clinical information available in the studies selected are summarized in [Table 1A](#t0005){ref-type="table"}. The gender distribution was highly heterogeneous for both PD patients (women proportion = 0.43, ranging from 0 to 0.88 across studies; 95% confidence interval = 0.36--0.49; I^2^ = 79.9%; p \< 0.001) and healthy controls (women proportion = 0.42, ranging from 0 to 0.7; 95% confidence interval = 0.34--0.49; I^2^ = 81%; p \< 0.001). When comparing PD patients with healthy controls, the numbers of men and women were similar across studies (odds ratio = 0.96; 95% confidence interval = 0.79--1.16; I^2^ = 0%; p = ns). The mean age was similarly heterogeneous for PD patients (range = 56--75 years; mean = 66.19; 95% confidence interval = 64.97--67.42; I^2^ = 89%; p \< 0.001) and for healthy controls (range = 55--73 years; mean = 64.87; 95% confidence interval = 63.25--66.50; I^2^ = 91%; p \< 0.001). The comparison between PD patients and controls was neither significant (p = ns) nor heterogeneous (I^2^ = 0%; p = ns). The disease duration displayed high heterogeneity for PD patients (range = 0.5--12.2 years; mean = 6.08; 95% confidence interval = 5.32--6.85; I^2^ = 96.9%; p \< 0.001).

3.2. MRI acquisition parameters {#s0060}
-------------------------------

MRI acquisition parameters available in the studies selected are summarized in [Table 1B](#t0010){ref-type="table"}. The parameters were highly variable, and some heterogeneity was observed for the voxel size (range: from 0.86 × 0.86 × 3 to 3.4 × 3.4 × 3 mm^3^), the number of directions (range: from 6 to 75 directions), and the field strength (range: from 1.5 to 4 T). Moreover, the b factor values (range = 800--2800), the echo time (range = 55--116) and the repetition time (range = 900--17,300) were also highly heterogeneous.

3.3. Disease effect size (D~ES~) {#s0065}
--------------------------------

At the clustering level ([Table 2](#t0015){ref-type="table"}), significant differences in FA-D~ES~ and MD-D~ES~ were found between PD patients and healthy controls in subcortical and cortical areas. In white matter, this was also the case for FA-D~ES~ only, and no significant differences were found in the cerebellum. MD-D~ES~ was highly heterogeneous in all significant clusters except in cortical areas (I^2^ = 34.5%).Table 2Disease effect size (D~ES~) and heterogeneity index (I^2^) for FA and MD according to the subcortical, white matter, cortical and cerebellar regions.Table 2FAMDN^studies^N^data^D~ES\ (p-value)~I^2^~(p-value)~N^studies^N^data^D~ES\ (p-value)~I^2^~(p-value)~Cluster 1 - subcortical**2072− 0.245**[⁎⁎](#tf0010){ref-type="table-fn"}**82.6%**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**15490.381**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**63.1%**[⁎⁎⁎](#tf0015){ref-type="table-fn"} Substantia nigra**1630− 0.706**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**75.9%**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**10160.635**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**23.5%** Putamen10160.27385.2%[⁎⁎⁎](#tf0015){ref-type="table-fn"}**7110.338**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**0%** Thalamus510− 0.32080.9%[⁎⁎⁎](#tf0015){ref-type="table-fn"}5110.26064.6%[⁎⁎](#tf0010){ref-type="table-fn"} Caudate nucleus**470.406**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**0%**46− 0.15991.1%[⁎⁎⁎](#tf0015){ref-type="table-fn"} Pallidum34− 0.27053%**340.533**[⁎⁎](#tf0010){ref-type="table-fn"}**0%** Pedonculopontine nucleus140.0290% Red nucleus110.332^(NA)^NA^(NA)^110.780^(NA)^NA^(NA)^Cluster 2 - white matter**17104− 0.148**[⁎](#tf0005){ref-type="table-fn"}**71.6%**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**121060.04142.3%**[⁎⁎⁎](#tf0015){ref-type="table-fn"} Corpus callosum**846− 0.188**[⁎⁎](#tf0010){ref-type="table-fn"}**31.1%**[⁎](#tf0005){ref-type="table-fn"}**5320.262**[⁎](#tf0005){ref-type="table-fn"}**52.1%**[⁎⁎⁎](#tf0015){ref-type="table-fn"} Corticospinal tract**4170.531**[⁎](#tf0005){ref-type="table-fn"}**89.8%**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**348− 0.156**[⁎⁎](#tf0010){ref-type="table-fn"}**4.9%** Fasciculus longitudinal39− 0.02850.8%[⁎](#tf0005){ref-type="table-fn"}110.751^(NA)^NA^(NA)^ Capsules26− 0.63184.4%[⁎⁎⁎](#tf0015){ref-type="table-fn"}**260.311**[⁎](#tf0005){ref-type="table-fn"}**0%** Cingulum23− 0.36261.8%230.31620.9% Pons230.41956.2%110.041^(NA)^NA^(NA)^ Corona radiate230.0110%230.22168.1%[⁎](#tf0005){ref-type="table-fn"} Optic tract**18− 0.659**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**26.8%**18− 0.0374.4%[⁎⁎⁎](#tf0015){ref-type="table-fn"} Fasciculus uncinate14− 0.1640%140.0700% Fornix**12− 2.169**[⁎⁎](#tf0010){ref-type="table-fn"}**74.7%**[⁎](#tf0005){ref-type="table-fn"} Centrum semiovale120.0520% Nigrostriatal tract11− 0.297^(NA)^NA^(NA)^Cluster 3 - cortical**1089− 0.740**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**75.7%**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**6180.418**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**34.5%** Frontal**722− 0.774**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**79.7%**[⁎⁎⁎](#tf0015){ref-type="table-fn"}280.17955%[⁎](#tf0005){ref-type="table-fn"} Cingulate**425− 0.486**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**66.5%**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**140.509**[⁎⁎](#tf0010){ref-type="table-fn"}**1.1%** Parietal**515− 0.648**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**47.8%**[⁎](#tf0005){ref-type="table-fn"}120.5000% Temporal**514− 1.196**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**83.8%**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**120.605**[⁎⁎](#tf0010){ref-type="table-fn"}**0%** Occipital**312− 0.694**[⁎⁎](#tf0010){ref-type="table-fn"}**78.5%**[⁎⁎⁎](#tf0015){ref-type="table-fn"} Olfactory11− 2.699^(NA)^NA^(NA)^**220.848**[⁎⁎](#tf0010){ref-type="table-fn"}**0%**Cluster 4 - cerebellum**517− 0.24680.4%**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**350.12839.6%** Cerebellar peduncle510− 0.09477.2%[⁎⁎⁎](#tf0015){ref-type="table-fn"}120.3240% Cerebellum27− 0.46884.4%[⁎⁎⁎](#tf0015){ref-type="table-fn"}230.02665.2%**All38282− 0.363**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**78.3%**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**251820.182**[⁎⁎⁎](#tf0015){ref-type="table-fn"}**54%**[⁎⁎⁎](#tf0015){ref-type="table-fn"}[^2][^3][^4][^5][^6]

At the anatomical level ([Table 2](#t0015){ref-type="table"}), five regions demonstrated significant differences between PD patients and healthy controls for both FA-D~ES~ and MD-D~ES~. Four of these regions showed a decrease of FA-D~ES~ and an increase of MD-D~ES~: the SN, the corpus callosum, the cingulate and the temporal cortices. The remaining region, localised in the corticospinal tract, showed an opposite change, that is increased FA-D~ES~ and decreased MD-D~ES~. All regions were heterogeneous for the FA-D~ES~, but only the corpus callosum was heterogeneous for the MD-D~ES~ (I^2^ = 52.1%). A single region with a significant difference between PD patients and healthy controls was found for FA-D~ES~ only, in the caudate nucleus (increased FA-D~ES~). For the MD-D~ES~ only, 4 areas (the putamen, the pallidum, the internal and external capsules, and the olfactory cortex) displayed significant differences between PD patients and controls ([Fig. 2](#f0010){ref-type="fig"}). None of these regions was associated with any significant heterogeneity of D~ES~.Fig. 2Brain areas identified following the meta-analysis and associated with significant differences between PD patients and healthy controls for FA-D~ES~ and MD-D~ES~, performed together or separately.The framed results correspond to an opposite pattern of results (i.e. FA-D~ES~ increase and MD-D~ES~ decrease for the corticospinal tract; FA-D~ES~ increase for the caudate nucleus).Fig. 2

3.4. Correlations between the main variables (FA-D~ES~ and MD-D~ES~) and the clinical, demographic and MRI parameter co-variables {#s0070}
---------------------------------------------------------------------------------------------------------------------------------

Demographic and clinical variables displayed correlations with the MD-D~ES~ of our meta-analysis ([Fig. 3](#f0015){ref-type="fig"}): The results in white matter was influenced by a gender effect (R = 0.93; p = 0.002), as well as the disease duration (R = − 0.73; p = 0.03).Fig. 3Significant positive (red) and negative (blue) correlations between the main variables (FA-D~ES~ and MD-D~ES~) and the selected co-variables, according to the pre-defined anatomical clusters.How to read this figure? For example: in cortical areas, there is a positive correlation between the FA-D~ES~ and the voxel size used for the MRI acquisition of the DTI and in white matter, there is a negative correlation between the MD-D~ES~ and the age of the participants. The larger the dot, the stronger the correlation. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 3

MRI parameters were also highly correlated with D~ES~ ([Fig. 3](#f0015){ref-type="fig"}). FA-D~ES~ was correlated with the field strength in cerebellum (R = − 0.83; p = 0.043). For MD-D~ES~, the number of DTI directions and the TE were correlated in white matter (respectively: R = − 0.92, p = 0.007; R = − 0.91, p = 0.003) and cortical areas (respectively: R = − 0.95, p = 0.0008; R = − 0.82, p = 0.04). In addition, MD-D~ES~ was correlated, in white matter, with the field strength (R = − 0.88; p = 0.007) and the TR (R = − 0.81; p = 0.03).

3.5. FA-D~ES~ and MD-D~ES~ in SN are influenced by dopaminergic state {#s0075}
---------------------------------------------------------------------

FA-D~ES~ and MD-D~ES~ in SN, either off- or on-medication, were statistically significant (p \< 0.001; see [Fig. 4](#f0020){ref-type="fig"}). When comparing the two states, we did not observe any difference between off- and on-medication states for MD-D~ES~ (Off: MD-D~ES~ = 0.635; On: MD-D~ES~ = 0.65), but a difference was found for FA-D~ES~ (Off: FA-D~ES~ = − 0.737; On: FA-D~ES~ = − 0.519). Significant heterogeneity was found only for off-medication FA-D~ES~ (I^2^ = 67%; p \< 0.001). I^2^ was low for both dopaminergic states in MD-D~ES~ (I^2^ \< 30%) and moderate for FA in on-medication (30% \< I^2^ \< 60%).Fig. 4FA-D~ES~ (in pink) and MD-D~ES~ (in green) in the Substantia Nigra of PD patients with (On) and without (Off) medication.Each dot corresponds to the Z-scored D~ES~ calculated from the data provided by the selected studies. The more FA dots there are on the left, the smaller the FA is for PD patients compared with healthy controls. D~ES~: disease effect size (Z-scored); FA: fractional anisotropy; MD: Mean diffusivity.Fig. 4

4. Discussion {#s0080}
=============

4.1. Summary of the findings {#s0085}
----------------------------

Our meta-analysis demonstrated that DTI was able to address structural differences between PD individuals and healthy controls, particularly in five cerebral regions sensitive to both FA and MD: the SN, the corpus callosum, the cingulate and temporal cortices, and the corticospinal tract. This latter region, contrary to the others, was associated with increased FA-D~ES~ and decreased MD-D~ES~, suggesting possible brain reorganization. Five brain areas were highlighted by only one of the two indicators, either FA-D~ES~ or MD-D~ES~: the putamen, the pallidum, the internal and external capsules, and the olfactory cortex, which showed tissue lesions in PD patients compared with controls. This was not the case for the caudate nucleus, for which FA-D~ES~ suggested a specific reorganization of this nucleus. Therefore, we observe an effect of the medication state in SN for FA-D~ES~, but not for MD-D~ES~. Regarding the correlation results, FA-D~ES~ was less dependent on co-variables than MD-D~ES~, particularly for white matter. In the following, since cerebellar areas did not show any difference in FA-D~ES~ or MD-D~ES~ between individuals with PD and healthy controls, we discuss our results regarding the remaining 3 pre-defined anatomical regions: subcortical nuclei (SN, putamen, pallidum and caudate nucleus), cortical areas (cingulate, temporal, olfactory) and white matter (corpus callosum and corticospinal tract). We do not discuss the data when FA-D~ES~ and MD-D~ES~ were reported by only one study, or when D~ES~ was significant only for FA or MD and significantly heterogeneous. Finally, we consider the information about clinical and MRI parameters as potential limitations of our analyses in order to further interpret our findings.

4.2. Pathophysiological and clinical implications of our findings {#s0090}
-----------------------------------------------------------------

### 4.2.1. Subcortical nuclei {#s0095}

Changes in FA and/or MD in the SN due to PD is a controversial issue: no differences for both FA and MD, as well as an increase in FA, were reported ([@bb0285], [@bb0510]), while other studies reported decreases in FA in the SN ([@bb0055], [@bb0060], [@bb0090], [@bb0095], [@bb0195], [@bb0360], [@bb0370], [@bb0380], [@bb0405], [@bb0485], [@bb0540], [@bb0345], [@bb0545], [@bb0560], [@bb0570]) and/or increases in MD ([@bb0100], [@bb0225], [@bb0260], [@bb0310], [@bb0425], [@bb0435]). Moreover, correlations between PD severity and FA were found both significant ([@bb0055], [@bb0560]) and not significant ([@bb0090]). It has also been shown that FA would be able to distinguish healthy subjects from de novo PD individuals, especially in the caudal region of the SN ([@bb0485]). Thus, DTI in the SN should help to distinguish PD patients from healthy controls, and possibly to detect individuals susceptible to developing PD: in fact, FA was found sensitive enough to distinguish healthy controls from controls who have been exposed to chemicals for about 20 years, and identified as a population at risk of developing PD ([@bb0100]). Our results do not allow concluding to a possible ability of DTI to track PD progression. Nevertheless, previous studies reported that DTI (with FA, MD, radial and axial diffusivity) is able to track progression of the SN longitudinally in PD ([@bb0260], [@bb0335], [@bb0575]). Moreover, the DTI changes in SN seem to be linked with bradykinesia, cognitive status ([@bb0335]) and dopaminergic deficit ([@bb0575]). First, the patient movement depending on the dopaminergic state during scanning (e.g., tremor when "off" or dyskinesia when "on") could be an argument in favour of image acquisition deterioration. It is also conceivable that medication states induced a neuroimaging artefact in the form of an increase in gray matter volume in the midbrain (substantia nigra, tegmental ventral area and subthalamic nucleus) previously reported with VBM ([@bb0420]), but not with DTI ([@bb0065]). In fact, levodopa could have intrinsic magnetic properties that could induce a variation in signal intensity and lead to a misclassification of voxels as part of gray or white matter. The interaction of dopaminergic treatments with iron (chelation or binding) could also partly explain this effect ([@bb0045]). Previous meta-analyses did not take this effect into account ([@bb0070], [@bb0435]), and future studies should pay attention to medication states, particularly for the investigation in the SN, as a precaution principle.

Regarding the putamen and the pallidum, our analysis showed a significant increase in MD-D~ES~, as already demonstrated ([@bb0290], [@bb0310]) and supporting the idea of a degeneration of the pallidum in PD patients compared with controls ([@bb0395]). This result is still a matter of debate since previous DTI studies also failed to detect such differences in the putamen ([@bb0125], [@bb0360], [@bb0260], [@bb0310]) and the pallidum ([@bb0125]), even suggesting that the pallidum can be spared in PD ([@bb0125]). DTI of the putamen and pallidum does not seem particularly discriminating and using other DTI indexes (e.g., orientation dispersion index, longitudinal diffusivity) could be helpful to provide significant differences in these subcortical regions ([@bb0225], [@bb0380]).

The caudate nucleus was associated with significantly increased FA-D~ES~ for PD patients compared with healthy controls, but with no change in MD-D~ES~ ([@bb0125], [@bb0195], [@bb0260], [@bb0310], [@bb0380]). This increase would reveal a selective neurodegeneration, reflecting much likely some gliosis ([@bb0040]) as already reported in Parkinsonian syndromes ([@bb0365]). One can also imagine an alternative interpretation that would lead to consider a potential compensatory reorganization previously reported using functional connectivity ([@bb0180]). However, some studies also reported degeneration of the caudate nucleus using VBM ([@bb0400], [@bb0515], [@bb0565], [@bb0105], [@bb0170], [@bb0230], [@bb0330]) or DTI (e.g., [@bb0280], [@bb0510], [@bb0410]). These latter studies were not included in our meta-analysis, since they did not fulfil the inclusion criteria: DTI investigation of the caudate nucleus requires further studies in order to draw robust conclusions on this point. Post-mortem observations could be an option to objectify possible reorganization of this nucleus.

### 4.2.2. Cortical areas {#s0100}

In general, our meta-analysis showed that the D~ES~ in cortical regions were highly heterogeneous for FA. More specifically, the D~ES~ of the temporal and cingulate cortices displayed a significant increase in MD and a significant decrease in FA. While PD patients without cognitive decline present no FA changes in temporal regions when compared with healthy controls ([@bb0375]), temporal cortex degeneration has been associated with cognitive status decline ([@bb0080], [@bb0050]). Using a classification analysis, superior temporal regions have been shown to be discriminant between healthy controls and PD ([@bb0345]). Similarly, cingulate cortex changes were correlated to cognitive performance ([@bb0215], [@bb0580]) and can help to discriminate PD patients with dementia from healthy controls ([@bb0080], [@bb0270]). All these findings taken together suggest that the cognitive status of PD patients is principally associated with perceptible damage in the temporal and cingulate cortices.

For the olfactory cortex, our meta-analysis showed a significant increase in MD in individuals with PD compared with healthy controls. In accordance with the Braak model of temporal degeneration in PD, considering the olfactory cortex as an early degenerative structure ([@bb0155]), two studies included in our analysis aimed at testing the possibility of the structural changes in the olfactory tract identified by DTI as a biomarker for PD diagnosis ([@bb0405], [@bb0425]). In fact, they reported FA and MD changes between PD patients and healthy controls, and a correlation between olfactory performance test and motor scores ([@bb0405], [@bb0425]). However, these studies did not involve any de novo PD patients. Another study, using DTI and statistical modelling, recently suggested that olfactory regions were particularly efficient at distinguishing de novo drug-naïve PD patients from healthy controls ([@bb0320]). It is too early to conclude about the sensitivity and specificity of DTI in olfactory regions as a biomarker of PD, but the results of our meta-analysis suggest that it could be used by clinicians as an additional measure.

### 4.2.3. White matter {#s0105}

MD-D~ES~ in white matter was highly correlated with demographic and clinical data, as well as with MRI parameters. Our analyses displayed significant changes in FA-D~ES~ (decrease) and MD-D~ES~ (increase) in the corpus callosum. It has been shown that the deterioration of the corpus callosum genu is linked to PD dementia ([@bb9550]), as well as executive and attention dysfunctions ([@bb0580]). DTI of the corpus callosum (in the body and the splenium) can help differentiating PD patients according to their cognitive status (normal, mild cognitive impairment, or dementia; [@bb0080]); for this purpose, MD demonstrated to be more accurate than FA ([@bb0525]). In addition, structural alteration of the corpus callosum, shown using DTI, seems to be involved in predominant gait disorders ([@bb0060]) and impulse control disorders ([@bb0535]). Other studies did not observe any change in FA and MD, and did not report any correlations with clinical assessments ([@bb0030], [@bb0185]). The corpus callosum is probably injured in PD, possibly in advanced stages of PD ([@bb0155]).

We also observed a significant FA-D~ES~ increase and a MD-D~ES~ decrease in the corticospinal tract, suggesting a reorganization of these fibers that can be interpreted as either a compensatory mechanism as a "*response to \[the\] decreased input from the thalamus and striatum*", or a selective neurodegeneration where increase of FA should be the "*consequence of altered pallido-thalamic activity*" ([@bb0295]). The increase in FA possibly reflects an increase in axonal density in some pathways, as the result of axonal sprouting ([@bb0015]). This is in line with other previous studies using DTI ([@bb0125], [@bb0215], [@bb0080], [@bb0325]). Regarding the internal and external capsules, a significant increase in MD-D~ES~ was barely observed in our analysis, as previously observed ([@bb0560]). A correlation between the increase in MD in the internal capsule and the increase in the UPDRS motor score ([@bb0490]), as well as between FA, MD and gait difficulty ([@bb0250]), was also reported. Altogether, these findings suggest that degenerations of the internal and external capsules are possible additional markers of PD.

4.3. Methodological considerations {#s0110}
----------------------------------

Several limitations of our meta-analysis have to be acknowledged, mainly based on the characteristics of the anatomical structures and the technical DTI acquisition parameters. Consequently, and more specifically, the correlations we found should be interpreted with caution. To a certain extent, they suggested some sensitivity of FA and MD (in several territories) to other factors, such as demographics, clinical data and MRI parameters. But it is difficult to draw any robust conclusion regarding causality relationships between factors. Nevertheless, these factors should be considered in future research in order to control as much as possible influences on DTI acquisition.

### 4.3.1. From an anatomical perspective {#s0115}

DTI results depend on the nature of the structures studied. DTI is particularly dedicated to the exploration of deep white matter (where inter-individual variability is restricted), while for the gray matter and cortico-spinal fluid, the evaluation is more uncertain ([@bb0200]). Areas with a low FA score (below 0.2) should be interpreted with caution (generally, these areas are located in the cortex; [@bb0265]), "because axon and dendrite orientations are not normally aligned \[...\] in human cortex" ([@bb0300]).

### 4.3.2. From a technical perspective {#s0120}

Many studies aimed at determining the best criteria to limit artefacts in DTI acquisition ([@bb0120]). [@bb0480] defined a spatial resolution yielding acceptable artefact reduction: 2 × 2 × 2 mm^3^, and [@bb0495] considered that a high spatial resolution should be fixed at 1 mm^3^ (particularly for crossing-fiber regions; [@bb0340]). Moreover, it is recommended to use a 3 T MRI to reduce the noise (for all tissues), despite a possible increase in spatial distortions ([@bb0010]). [@bb0205] recommended to use at least 30 diffusion directions, in order "*to obtain robust estimates of tensor-derived properties*"; [@bb0315] only observed differences of FA between 6, 21 and 31 directions for regions with low anisotropy ([@bb0315]). As much as possible, the use of parallel image acquisitions (for example, with generalized auto-calibrating partially parallel acquisition; [@bb0135]) seems to be recommended. Moreover, the software algorithms used to calculate DTI parameters could introduce variability, but each software presents its own strengths and weaknesses ([@bb0255]). It is also possible to use other MR acquisition schemes, for example diffusion spectrum imaging, to enhance DTI acquisition. This method, with longer acquisition duration than DTI (from 15 to 60 min), makes it possible to measure fiber crossing ([@bb0140]). Studies using VBM are quite numerous, and very informative as well; in order to ensure an exhaustive and non-invasive study of pathophysiology of PD, combining DTI and VBM analyses represents a very good option that should be considered when studying PD cortical degeneration.

5. Conclusion {#s0125}
=============

Our meta-analysis aimed at providing a quantitative evaluation of structural brain changes associated with PD. We showed that DTI is particularly relevant for subcortical areas (lesions in the SN, the putamen and the pallidum, and a possible reorganization or a selective neurodegeneration in the caudate nucleus). It is also informative for cortical areas and white matter. DTI evaluation of structural lesions remains difficult, due to the variability in PD pathophysiology and MRI acquisition parameters (e.g. artefacts and nature of the region of interest). However, our meta-analysis and literature review contributes to significantly increasing our knowledge of PD pathophysiology. It also addresses the interesting possibility of follow-up of the disease severity and associated brain structural modulations using in vivo imaging. From our review and meta-analysis, we can summarize the following points: DTI in olfactory regions could participate to the diagnosis of PD; FA and MD in SN are good indicators to identify PD patients, but also for PD progression; The corpus callosum degenerates in PD, but with a high variability; its integrity is correlated to specific symptoms (e.g., impulse disorders, gait); The caudate nucleus and cortico-spinal tract show an increase in FA and decrease in MD but further studies are required to conclude about the nature of these variations and their possible link with a degenerative process; As a precaution, PD patients should be assessed while not under medication; DTI in structures with non-uniform white fibers organization should be avoided, such as in cortical regions. Despite some limitations, DTI appears as a sensitive method to study PD pathophysiology and severity. The association of DTI with other MRI methods (VBM; generalized autocalibrating partially parallel acquisition; Diffusion Spectrum Imaging) should be considered to study brain alterations in PD.
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[^1]: N: study; y: years; UPDRS: Unified Parkinson\'s Disease Rating Scale (III: motor scale); PD: Parkinson\'s disease; HC: healthy control; PDD: Parkinson\'s disease with dementia; Dep: depression; MCI: mild cognitive impairment; FOG: freezing of gait; VH: visual hallucination; RBD: Rapid Eye Movement sleep behavior disorders; \[on\]/\[off\]: with/out dopaminergic treatment; na: not available.

[^2]: D~ES~: disease effect size; FA: fractional anisotropy; MD: mean diffusivity; I^2^: heterogeneity index; N^data^: number of data included; N^studies^: number of different studies included. NA: insufficient number of data to perform statistical analysis.

[^3]: Regions that have a significant effect size for FA or MD are highlighted in bold.

[^4]: p \< 0.05.

[^5]: p \< 0.01.

[^6]: p \< 0.001.
